Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus PMB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE ETHINYL ESTRADIOL versus PMB 200.
NORGESTIMATE; ETHINYL ESTRADIOL vs PMB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
PMB 200 is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB). The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The CCB component inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, resulting in peripheral vasodilation and decreased blood pressure.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
2.5 mg orally once daily, increased to 5 mg after 2 weeks if tolerated; maximum 10 mg once daily.
None Documented
None Documented
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Terminal elimination half-life 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min), necessitating dose adjustment
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Renal (80% unchanged, 15% as glucuronide conjugate), biliary/fecal (5%)
Category D/X
Category C
Progestin + Estrogen
Estrogen/Progestin Combination